| Literature DB >> 31056398 |
Jo Ishizawa1, Sarah F Zarabi2, R Eric Davis3, Ondrej Halgas4, Takenobu Nii1, Yulia Jitkova5, Ran Zhao1, Jonathan St-Germain5, Lauren E Heese1, Grace Egan5, Vivian R Ruvolo1, Samir H Barghout2, Yuki Nishida1, Rose Hurren5, Wencai Ma6, Marcela Gronda5, Todd Link7, Keith Wong4, Mark Mabanglo8, Kensuke Kojima9, Gautam Borthakur1, Neil MacLean5, Man Chun John Ma3, Andrew B Leber5, Mark D Minden2, Walid Houry10, Hagop Kantarjian11, Martin Stogniew12, Brian Raught2, Emil F Pai13, Aaron D Schimmer14, Michael Andreeff15.
Abstract
The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic and chemical approaches, we showed that hyperactivation of the protease selectively kills cancer cells, independently of p53 status, by selective degradation of its respiratory chain protein substrates and disrupts mitochondrial structure and function, while it does not affect non-malignant cells. We identified imipridones as potent activators of ClpP. Through biochemical studies and crystallography, we show that imipridones bind ClpP non-covalently and induce proteolysis by diverse structural changes. Imipridones are presently in clinical trials. Our findings suggest a general concept of inducing cancer cell lethality through activation of mitochondrial proteolysis.Entities:
Keywords: acute myeloid leukemia; cancer; imipridone; lymphoma; mitochondrial ClpP; mitochondrial proteolysis; oxidative phosphorylation; respiratory chain complex
Mesh:
Substances:
Year: 2019 PMID: 31056398 PMCID: PMC6620028 DOI: 10.1016/j.ccell.2019.03.014
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743